Journey Medical Corporation (DERM) is scheduled to report 4th quarter earnings on 03/21/2024, after the market closes. Regarding Q4 estimates, Wall Street analysts expect Journey Medical Corporation to post earnings
Journey Medical Corporation (DERM) is scheduled to report 4th quarter earnings on 03/21/2024, after the market closes. Regarding Q4 estimates, Wall Street analysts expect Journey Medical Corporation to post earnings
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024 Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024
Journey Medical Corporation announced that the FDA has accepted the Company’s New Drug Application, NDA, for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults. The
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 36th Annual